Accelerating Innovation at Leica Biosystems

Putting It All Together PRE-2019 ANTICIPATED CORE REVENUE GROWTH FUTURE ANTICIPATED CORE GROWTH RATE DANAHER 5-6% Owned Dental (Envista) MSD+ cytiva 6-7% expected DHR did not own HSD Now part of DHR Life Sciences Uniquely positioned across bioprocessing ~$3B 2021E revenue (>10% of DHR) LDD ~$1B 2019 revenue (5% of DHR) LDD Cepheid >40% installed base growth last 18mos Durable testing tailwinds REST OF DANAHER MSD MSD+ Benefit from continued investment spend Expect core growth profile to increase from 2019 DANAHER

View entire presentation